Can-Fite Biopharma Ltd ADR [AMEX: CANF] closed the trading session at $1.20.
The stocks have a year to date performance of -26.15 percent and weekly performance of -14.16 percent. The stock has been moved at -56.36 percent over the last six months. The stock has performed -26.32 percent around the most recent 30 days and changed -24.53 percent over the most recent 3-months.
If compared to the average trading volume of 280.91K shares, CANF reached to a volume of 349392 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Can-Fite Biopharma Ltd ADR [CANF]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CANF shares is $7.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CANF stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Can-Fite Biopharma Ltd ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 11, 2017. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on October 19, 2016, representing the official price target for Can-Fite Biopharma Ltd ADR stock. Previously, the target price had yet another raise to $6, while Rodman & Renshaw analysts kept a Buy rating on CANF stock. On November 30, 2015, analysts increased their price target for CANF shares from 4 to 6.
CANF stock trade performance evaluation
Can-Fite Biopharma Ltd ADR [CANF] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.16. With this latest performance, CANF shares dropped by -26.32% in over the last four-week period, additionally sinking by -56.36% over the last 6 months – not to mention a drop of -42.31% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CANF stock in for the last two-week period is set at 37.18, with the RSI for the last a single of trading hit 33.85, and the three-weeks RSI is set at 39.46 for Can-Fite Biopharma Ltd ADR [CANF]. The present Moving Average for the last 50 days of trading for this stock 1.5474, while it was recorded at 1.3120 for the last single week of trading, and 2.0608 for the last 200 days.
Can-Fite Biopharma Ltd ADR [CANF]: Institutional Ownership
There are presently around $1.28%, or 1.28%% of CANF stock, in the hands of institutional investors.
